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Objective: Maternal thyroid disease (TD) during pregnancy is associated with adverse birth 
outcomes, but little is known on its long-term outcomes. We aimed to examine if children born 
to mothers with TD have increased disease risk during childhood and adolescence.
Patients and methods: A register-based cohort study was conducted on all live born children 
in Denmark from 1989 to 2013, including the association between maternal TD during pregnancy 
and somatic and psychiatric diseases in the children. Cox proportional hazards models were 
used to compute hazard ratios (HRs) according to the type of maternal TD, Graves’ disease, 
and Hashimoto’s thyroiditis.
Results: A total of 2,618 children were born to women with Graves’ disease, 760 to women 
with Hashimoto’s thyroiditis (exposed), and 1,557,577 to women without any TD (unexposed). 
The median follow-up time for children born to mothers with Graves’ disease was 9.3 years 
(25/75 percentile 5.4/13.9 years) and with Hashimoto’s thyroiditis was 4.8 years (25/75 percentile 
2.5/8.2 years). In children exposed to maternal Graves’ disease in utero, the adjusted HR of TD 
was 12.83 (95% CI, 9.74–16.90), Graves’ disease was 34.3 (95% CI, 20.23–58.35), and type 1 
was diabetes 2.47 (95% CI, 1.46–4.18). In children exposed to maternal Hashimoto’s thyroiditis, 
the adjusted HR of Hashimoto’s thyroiditis was 24.04 (95% CI, 5.89–97.94).
Conclusion: Our data suggest that children born to women with Graves’ disease and Hashimoto’s 
thyroiditis have excess long-term morbidities in childhood and adolescence. We particularly 
found an increased risk of any TD and type 1 diabetes to be diagnosed in children exposed in utero 
to Graves’ disease. These novel findings are relevant for pediatricians, stressing the importance 
of history of maternal disease when evaluating children with suspected endocrine disorders.
Keywords: thyroid disease, Graves’ disease, Hashimoto’s thyroiditis, reproduction, child 
morbidity, clinical epidemiology
Introduction
Thyroid diseases (TDs) are among the most prevalent chronic diseases in pregnant 
women and the prevalence has increased during the last decades.1–3 In Denmark, the 
two most frequent TDs are Graves’ disease with a prevalence of 4.51 cases per 1,000 
inhabitants and Hashimoto’s thyroiditis with a prevalence of 0.58 cases per 1,000 inhab-
itants.4 These autoimmune diseases primarily affect women, with a male:female ratio 
for Graves’ disease of 1:5.6 and for Hashimoto’s thyroiditis of 1:8.0.5 Graves’ disease 
is caused by the presence of activating thyrotropin receptor stimulating IgG antibod-
ies (TRAbs) acting on the thyrotropin receptor. TRAb stimulates the thyroid hormone 
production in an unregulated manner, incapacitating the hypothalamic–pituitary axis 
and resulting in hyperthyroidism.6 In Hashimoto’s thyroiditis, the thyroid peroxidase 
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antibodies (TPOabs) are cytotoxic to the thyrocytes, lead-
ing to destruction of the thyroid gland and hypothyroidism.7 
Graves’ disease often goes into remission after the first treat-
ment years restoring a normal thyroid function and absence of 
autoantibodies, whereas Hashimoto’s thyroiditis is a chronic 
condition due to destruction of the thyroid tissue, resulting 
in a state of irreversible hypothyroidism requiring lifelong 
substitution with thyroid hormones. The TPOab level usually 
decreases over time. Therefore, even though the prevalence of 
Graves’ diagnosis codes is higher compared to Hashimoto’s, 
the number of patients being affected by the disease and 
attending long-term medical services in the community is 
significantly lower for Graves’ disease compared to Hashi-
moto’s thyroiditis.
When active autoimmune TD is present during pregnancy, 
the fetus will be exposed to circulating antibodies as both 
TRAb and TPOab pass the placenta from the mother to the 
fetus.8 In Graves’ disease, the presence of TRAb rarely causes 
intrauterine thyrotoxicosis and goiter of the fetus as preg-
nancy usually suppresses Graves’ disease.9,10 Furthermore, 
antithyroid medication has been found to pass the placenta 
in small amounts.11 In Hashimoto’s thyroiditis, the TPOabs 
have not been linked to fetal or neonatal TD.8
Maternal hyperthyroidism has been linked to miscarriage, 
stillbirth, preterm birth, intrauterine growth retardation, low 
birth weight, preeclampsia, and fetal TD.12,13 If the mother 
with Graves’ disease experiences overt hyperthyroidism dur-
ing pregnancy, the Danish Endocrine Society recommends 
treatment with the antithyroid medication propylthiouracil 
during the first trimester, and later changing the medication 
to methimazole during the second and third trimesters.14 Both 
of these medications have been associated with congenital 
malformations, especially methimazole with malformations 
arising during the first trimester.13,15 In addition, the long-
term effects of maternal hyperthyroidism on the offspring 
are linked to an increased risk of neurologic or psychiatric 
diseases including seizure, attention-deficit hyper activity 
disorders, and other psychiatric disorders.16–18
Maternal hypothyroidism, as Hashimoto’s thyroiditis, 
is associated with several adverse pregnancy and child out-
comes such as spontaneous abortion, intrauterine growth 
retardation, preeclampsia, and preterm birth.12,19 In a long-
term perspective, impaired neurodevelopment in the offspring 
has been suggested to be a result of maternal hypothyroxin-
emia during pregnancy.20–22 In one study, children of mothers 
with untreated hypothyroidism during pregnancy showed a 
significantly lower IQ than their peers.23 In addition, it has 
recently been observed that children born to mothers with 
hypothyroidism have an increased risk of hypertension, neu-
rologic and psychiatric diseases later in life.18,21,24
To our knowledge, no reports of a wider range of chronic 
somatic conditions as outcomes in the children of mothers 
with TD are available. We, therefore, aimed to examine the 
association between in utero exposure of the most prevalent 
diagnoses of maternal TD (Graves’ disease and Hashimoto’s 
thyroiditis) and the long-term risk of several chronic diseases 
in the offspring during childhood and adolescence. We 
hypothesized that active maternal TD during pregnancy has 
an impact on the developing fetus in a long-term perspective 
due to the intrauterine environment, antibodies, genetics, 
medication, or other unknown factors. Our study was based 
on a nationwide cohort of all live births during a 25-year 
period in Denmark with up to 25 years of follow-up.
Patients and methods
setting and data sources
In Denmark, all citizens have free and equal access to a 
tax-financed health care system and its uniform organiza-
tion enabled us to use a population-based study design. The 
Danish Civil Registration System was established in 1968 
and contains information on date of birth and death, sex, 
place of residence, and dates of emigration and immigration, 
with daily updates, and all residents have a personal iden-
tification number in The Danish Civil Registration System 
(the DCRS number). The DCRS number is a unique digit 
identifier used in all Danish health registries, and the DCRS 
number ensures valid linkage between the registries.25 A 
national cohort was established by linking the registries 
including information from the DCRS, the Danish Medical 
Birth Registry (DMBR) – a register that has information on 
all births in Denmark established in 1973,26,27 and the Danish 
National Registry of Patients (DNRP). The DNRP contains 
diagnoses of all inpatients admitted to a non-psychiatric 
public hospital in Denmark since 1977 and emergency and 
outpatient contacts since 1995. The diagnosis codes in the 
DNRP were assigned according to the eighth revision of the 
World Health Organization’s International Classification of 
Diseases (ICD-8) until the end of 1993, and according to the 
tenth revision (ICD-10) thereafter.28 From the Danish Psy-
chiatric Central Register (DPCR), we extracted information 
on psychiatric outcomes. The DPCR was established as a 
computerized nationwide register in 1969, and the register 
includes information on all psychiatric hospitalizations, 
including outpatient visits since 1995.
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study population
The study population comprised all live born children, born 
between January 1, 1989 and December 31, 2013 according 
to the DMBR.
Children born to women with 
autoimmune TD, exposed cohorts
To ensure active autoimmune maternal TD, data on mater-
nal TD were obtained within a period of 1 year before 
childbirth. The child was allocated to the exposed cohort if 
the mother was assigned with a diagnosis of autoimmune 
hyperthyroidism/Graves’ disease (ICD-8 codes: 242.00, 
242.01, 242.08, 242.09; ICD-10 code: E05.0) or autoim-
mune hypothyroidism/Hashimoto’s thyroiditis (ICD-8 code: 
244.01; ICD-10 codes: E06.3, E06.3A+E06.3B) within 1 
year before childbirth. We constructed two exposed cohorts: 
one cohort of children exposed in utero to maternal autoim-
mune hyperthyroidism/Graves’ disease and another cohort 
of children exposed in utero to maternal autoimmune hypo-
thyroidism/Hashimoto’s thyroiditis. Mothers registered with 
both diseases (Graves’ disease and Hashimoto’s thyroiditis) 
within 1 year before childbirth were allocated to the Graves’ 
disease group (21 mothers giving birth to 22 children). At 
the start of hyperthyroidism in Graves’ disease, TPOabs are 
present in many cases along with TRAbs,29 which may lead 
to the assignment of diagnoses of both Graves’ disease and 
Hashimoto’s thyroiditis. As TRAbs are specific for Graves’ 
disease in the state of hyperthyreosis, the presence of TPOab 
in this case is not assigned any pathological effect.6 In addi-
tion, TPOabs were found to be present in ~13% of Danish 
women in fertile age without any TD, indicating the low 
specificity of TPOabs.30
Children born to women without 
autoimmune TD, unexposed cohort
All live born children from the study population, born to 
women with no registered diagnoses of any TD within 1 year 
before childbirth, were allocated to the unexposed cohort.
long-term child morbidity outcome 
assessment
In order to report on chronic diseases during childhood and 
adolescence in children born to women with TD, the authors 
went through the entire ICD classification of diseases and 
reached consensus on 15 disease groups covering major non-
malignant somatic and psychiatric disease categories. These 
15 included disease categories were as follows: 1) chronic 
lung disease, including asthma, 2) TD, 2a) Graves’ disease, 
2b) Hashimoto’s thyroiditis, 3) parathyroid diseases, 4) type 
1 diabetes, 5) type 2 diabetes, 6) polycystic ovary syndrome 
(PCOS), 7) epilepsy, 8) multiple sclerosis (MS), 9) rheuma-
toid arthritis, 10) systemic lupus erythematosus (SLE), 11) 
inflammatory bowel disease (IBD), 12) coagulation disor-
ders, 13) anxiety and personality disorders, 14), affective 
mood disorders, and 15) schizophrenia and other paranoid 
psychoses. The included ICD codes are provided in Table S1.
statistical analysis and confounders
Initially, contingency tables were constructed for the main 
study variables of the exposed and unexposed cohorts. We 
used multivariate Cox proportional hazard regression models 
to compute the associations between maternal TD (stratified 
on Graves’ disease and Hashimoto’s thyroiditis) and offspring 
morbidity, in a cluster analysis accounting for multiple chil-
dren to the same mother.
Crude hazard ratio (HR) and adjusted hazard ratios (aHR) 
and the associated 95% CIs were reported. Follow-up started 
at the date of birth, but for the occurrence of child and adoles-
cence outcomes of chronic lung disease and asthma, and the 
psychiatric disorders, the follow-up period started from the 
age of 5 years. These diseases are in general not assigned to 
children aged <5 years of age, and the presence of the diagno-
ses before that age could be due to misclassification. Children 
in the cohorts were followed until the date of event (disease), 
death, or end of follow-up by December 31, 2014. Potential 
confounders were identified a priori based on the currently 
available scientific literature and applied to the statistical 
model.31 We extracted the following information related to 
childbirth from the DMBR: sex of the child, year of birth (in 
five calendar periods: 1989–1993, 1994–1998, 1999–2003, 
2004–2008, and 2009–2013), maternal age at birth (<20, 
20–29, 30–39, and >40 years), preterm birth defined as <37 
completed weeks of gestation (no/yes), small for gestational 
age defined as birth weight below –2 SD of the sex-specific 
expected birth weight (no/yes),32 mode of delivery (vaginal/ 
cesarean section), parity (1/≥2), multiple birth (no/yes), 
maternal smoking during pregnancy (no/yes; information 
on maternal smoking was collected in the registries from 
1991), and maternal pre-pregnancy body mass index (<18.5, 
18.5–24, 25–29, and >30; information on body mass index 
was available in the registries from 2003). Furthermore, we 
collected data on maternal comorbidity from the DNRP 
and the DPCR in the exposed and the unexposed cohorts. 
Adjustment for other maternal underlying chronic diseases 
was carried out and, for instance, when assessing the risk of 
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type 1 diabetes in the offspring, we adjusted for the effect 
of underlying maternal type 1 diabetes. The same approach 
was used when we estimated the risk of other child diseases 
(except in the analyses for Graves’ disease and Hashimoto’s 
thyroiditis where these diseases constituted the exposure). 
We only performed the adjusted analyses in disease groups 
with ≥10 childhood outcomes in the exposed groups, or a 
significant result in the crude analysis, and this was in order 
to ensure solid statistical precision.
All statistical analyses were performed using Stata Soft-
ware (v 14.0; StataCorp LP, College Station, TX, USA) and 
we chose a 5% level of significance.
The study was approved by The Danish Data Protection 
Agency (Journal no. 2013-41-2092) and followed the rules 
of security and privacy. According to Danish law, approval 
by the ethical review board or patient consent is not required 
for register-based studies.
Results
From 1989 to 2013, we included 1,560,955 live born children. 
A total of 3,378 of these children were exposed to maternal 
TD in terms of Graves’ disease and Hashimoto’s thyroiditis 
during pregnancy, of whom 2,618 were born to mothers with 
active autoimmune Graves’ disease and 760 children were 
born to mothers with active autoimmune Hashimoto’s thy-
roiditis. Thus, a total of 1,557,577 children born to women 
without any kind of TD were allocated to the unexposed 
cohort. In children born to mothers with Graves’ disease, 
the median follow-up time was 9.3 years (25/75 percentile 
5.4/13.9 years). In children born to women with Hashimoto’s 
thyroiditis, the median follow-up time was 4.8 years (25/75 
percentile 2.5/8.2 years).
The basic characteristics of the exposed cohort of chil-
dren born to women with Graves’ disease, the cohort of 
children born to women with Hashimoto’s thyroiditis, and 
the unexposed cohort are given in Table 1. The percentage 
of children born to women with Graves’ disease remained 
relatively constant from 2004 and onward (~30%). The 
percentage of children born to women with Hashimoto’s thy-
roiditis increased with increasing calendar time, and 60.9% 
of the children born to women with Hashimoto’s thyroiditis 
were thus born in the latest calendar period between 2009 
and 2013. The frequency of cesarean section in women 
with Graves’ disease and Hashimoto’s thyroiditis (24.3% 
and 26.2%, respectively) was significantly higher than the 
frequency of cesarean section among unexposed women 
(15.0%). In addition, mothers with Graves’ disease were 
more likely to experience a multiple birth (10.0%) compared 
to mothers with Hashimoto’s thyroiditis or with no TD (5.0% 
and 3.7%, respectively). Women with Graves’ disease were 
more likely to smoke during pregnancy (18.6%) than those 
with Hashimoto’s thyroiditis (6.8%). The proportion of 
smokers in the unexposed cohort was by comparison 18.7%.
long-term child morbidity when exposed 
to maternal graves’ disease
We found a total of 246 childhood disease outcomes in chil-
dren exposed in utero to Graves’ disease (n=2,618). There 
were no outcomes for childhood diseases of MS and SLE 
among the exposed children. We found that in utero exposure 
to Graves’ disease was associated with an increased risk of 
the development of selected chronic diseases in the outcome. 
The risk of TD was aHR 12.83 (95% CI, 9.74–16.90), Graves’ 
disease was aHR 34.33 (95% CI, 20.23–58.25), and type 1 
diabetes was aHR 2.47 (95% CI, 1.46–4.18). The crude HR 
of Hashimoto’s thyroiditis was 4.79 (95% CI, 1.54–14.90) 
and the crude HR for IBD was 2.31 (95% CI, 1.16–4.63); 
however, the results were not statistically significant after 
adjustment. The HRs and aHRs for childhood disease out-
come groups are shown in Figure 1.
long-term child morbidity when exposed 
to maternal hashimoto’s thyroiditis
We found a total of 33 childhood disease outcomes in chil-
dren exposed in utero to Hashimoto’s thyroiditis (n=760). 
These few outcomes were distributed across many different 
childhood disease groups, and we could therefore only per-
form a few adjusted analyses. There were no outcomes of 
parathyroid diseases, type 2 diabetes, PCOS, SLE, MS, IBD, 
coagulation disorders, and affective mood disorders. The 
crude HRs were increased for the TD diagnoses (including 
the subgroups of Graves’ disease and Hashimoto’s thyroiditis) 
and in the disease group of schizophrenia and other paranoid 
psychoses. After adjustment, the results remained significant 
for TD with aHR of 11.12 (95% CI, 5.53–22.34), in the sub-
group of Hashimoto’s thyroiditis with the aHR 24.02 (95% 
CI, 5.89–97.94), and in schizophrenia and other paranoid 
psychoses with the aHR 10.64 (95% CI, 2.80–40.41). The 
HRs and aHRs for childhood disease outcome groups are 
shown in Figure 2.
Discussion
To the best of our knowledge, this is the first study to 
examine the long-term consequences in children exposed 
to active, autoimmune maternal TD in utero in a wider per-
spective. In this large nationwide study on one of the most 
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prevalent chronic disease group during pregnancy,3 we found 
that children were more often exposed in utero to Graves’ 
disease compared to Hashimoto’s disease. We also found 
a relatively larger disease burden in children born to moth-
ers with Graves’ disease than in those born to women with 
Hashimoto’s disease. For several of the diagnostic groups 
examined, the point estimates indicated excess long-term 
morbidity in children exposed to active maternal TD. In 
general, the diseases with significantly increased risks in the 
Table 1 Characteristics of the cohorts (exposed and unexposed) at the time of birth
Maternal Graves’  
disease
n=2,618; n (%)
Maternal Hashimoto’s  
thyroiditis
n=760, n (%) 
No maternal Graves’ disease  
or Hashimoto’s thyroiditis
n=1,557,577, n (%)
Sex
girl 1,359 (51.9) 365 (48.0) 758,144 (48.7)
Boy 1,259 (48.1) 395 (52.0) 799,433 (51.3)
Year of birth
1989–1993 129 (4.9) 3 (0.4) 315,001 (20.2)
1994–1998 319 (12.2) 33 (4.3) 330,041 (21.2)
1999–2003 600 (22.9) 75 (9.9) 315,852 (20.3)
2004–2008 846 (32.3) 186 (24.5) 311,779 (20.0)
2009–2013 724 (27.7) 463 (60.9) 284,904 (18.3)
Preterm birth
no 2,310 (88.2) 701 (92.2) 1,450,763 (93.1)
Yes 298 (11.4) 58 (7.6) 94,905 (6.1)
Missing 10 (0.4) 1 (0.1) 11,909 (0.8)
SGA
no 2,448 (93.5) 720 (94.7) 1,472,222 (94.5)
Yes 144 (5.5) 28 (3.7) 59,427 (3.8)
Missing 26 (1.0) 12 (1.6) 25,928 (1.7)
Maternal age, years
<20 7 (0.3) 1 (0.1) 26,138 (1.7)
20–29 919 (35.1) 230 (30.3) 773,904 (49.7)
30–39 1,577 (60.2) 497 (65.4) 723,361 (46.4)
>40 115 (4.4) 32 (4.2) 34,174 (2.2)
Mode of delivery
Vaginal 1,982 (75.7) 561 (73.8) 1,323,283 (85.0)
Cesarean section 636 (24.3) 199 (26.2) 234,294 (15.0)
Birth order
1 971 (37.1) 319 (42.0) 705,230 (45.3)
≥2 1,647 (62.9) 441 (58.0) 852,347 (54.7)
Multiple birth
no 2,356 (90.0) 722 (95.0) 1,500,125 (96.3)
Yes 262 (10.0) 38 (5.0) 57,452 (3.7)
Maternal smokinga
no 1,965 (75.1) 689 (90.7) 1,085,628 (69.7)
Yes 486 (18.6) 52 (6.8) 290,839 (18.7)
Missing 167 (6.4) 19 (2.5) 181,110 (11.6)
Maternal BMIa
<18.5 59 (2.3) 29 (3.8) 23,584 (1.5)
18.5–24 935 (35.7) 387 (50.9) 350,724 (22.5)
25–29 327 (12.5) 127 (16.7) 119,054 (7.6)
>30 158 (6.0) 85 (11.2) 68,579 (4.4)
Missing 1,139 (43.5) 132 (17.4) 995,636 (63.9)
Note: ainformation on maternal smoking was available in the registries from 1991 and on BMi from 2003 and onward.
Abbreviations: BMi, body mass index; sga, small for gestational age.
children of the mothers with TD were identified within the 
group of autoimmune diseases, that is, TD, Graves’ disease, 
Hashimoto’s thyroiditis, and type 1 diabetes. Our findings 
are in accordance with familial association studies in which 
an aggregation of different autoimmune diseases has been 
reported.33
We found an increased risk of being diagnosed with 
TD (including the subgroup of Graves’ disease), and type 1 
diabetes when the offspring was exposed to active maternal 
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Graves’ disease in utero. In addition, we found that children 
exposed to active maternal Hashimoto’s thyroiditis in utero 
had an increased risk of being diagnosed with TD (includ-
ing the subgroup of Hashimoto’s thyroiditis), whereas the 
significantly increased crude HR for being diagnosed with 
Graves’ disease disappeared after the confounder adjustment. 
The increased risk of being diagnosed with type 1 diabetes 
in children exposed to Graves’ disease in utero is, to our 
knowledge, novel. In contrary, it is well established that 
type 1 diabetes is associated with a higher risk of developing 
other autoimmune diseases, where 15%–30% have autoim-
mune TD (especially, Hashimoto’s thyroiditis and rarely, 
Graves’ disease) and 4%–9% have celiac disease, suggest-
ing that these diseases share genetic susceptibility.34–36 The 
development of hyperthyroidism in type 1 diabetes has been 
linked to specific human leukocyte antigen haplotypes.36 The 
association of increased aHR for developing type 1 diabetes 
when exposed to Graves’ disease in utero may thus, in part, 
be explained by an inherited common genetic decisive factor 
for the two diseases.
It is suggested that the offspring of a parent suffering 
from a specific autoimmune disease carries a higher sus-
ceptibility for developing the same autoimmune disease as 
their parent, compared to the background population.37 This 
association was also present in this study as the children 
exposed to Graves’ disease had a significantly increased risk 
of developing Graves’ disease and the children exposed to 
Hashimoto’s thyroiditis in utero had a significantly increased 
risk for developing Hashimoto’s thyroiditis themselves later 
in childhood and adolescence. This points toward the pos-
sibility of an inherited causative genetic mutation for the 
diseases, which was investigated by Medici et al by a genome-
wide association study meta-analysis, revealing new genetic 
loci associated with the presence of TPOab and the risk of 
developing clinical TD including both hypo- and hyperthy-
roidism.38 Twin studies show that ~75% of the phenotypic 
Figure 1 hr and adjusted hr (bold) for chronic disease in the offspring of mothers with graves’ disease during pregnancy, log scale.
Notes: TD included all types of TDs and graves’ disease and hashimoto’s thyroiditis as subgroups. adjustments were only made in groups with more than ten outcomes or 
a significant result in the crude analysis. Crude HRs were adjusted for sex of the child, year of birth, maternal age at birth, delivery mode, multiple birth, birth order, preterm 
birth, sga, and maternal comorbidity of the outcome disease. TD included the following diagnoses: iCD-8: 240, 241, 242 (except 242.00), 243, 244 (except 244.01), 246, 
245.02, 245.03, 245.04, 245.08; iCD-10: E00, E01, E02, E03, E04, E05 (except E05.0), E06, E07. graves’ disease consisted of the following diagnoses: iCD-8: 242.00, 242.01, 
242.08, 242.09 and iCD-10: E05.0. hashimoto’s thyroiditis consisted of the following diagnoses: iCD-8: 244.01 and iCD-10: E06.3, 06.3a, E06.3B.
Abbreviations: Exp, exposed; HR, hazard ratio; ICD, International Classification of Diseases; SGA, small for gestational age; TD, thyroid disease; Unexp, unexposed.
Disease Exp2,618
Unexp
1,557,577 HR 95% Cl
Chronic lung disease, including asthma
TD
- Graves’ disease
- Hashimoto’s thyroiditis
Parathyroid diseases
Type 1 diabetes
Type 2 diabetes
Polycystic ovary syndrome
Epilepsy
Multiple sclerosis
Rheumatoid arthritis
Systemic lupus erythematosus
Inflammatory bowel disease
Coagulation disorders
Anxiety and personality disorders
Affective mood disorders
Schizophrenia and other paranoid 
psychoses
63
58
14
3
1
15
1
2
30
0
7
0
8
2
32
6
4
44,106
4,404
542
705
213
5,106
576
1,854
19,997
296
4,518
293
4,574
2,513
28,287
5,645
5,777
1.21
1.25
14.47
12.83
34.64
34.33
4.79
1.31
4.77
2.57
2.47
3.01
2.31
1.82
0.8
1.24
1.17
1.99
1.13
0.20 0.50 1.0 2.0 5.0
HR
Crude
Adjusted
10.0 20.0 50.0 100.0
1.12
1.04
1.28
2.02
0.94–1.56
0.95–1.64
11.00–19.04
9.74–16.90
20.45–58.67
20.23–58.25
1.54–14.90
0.46–3.69
0.67–33.97
1.55–4.27
1.46–4.18
0.42–21.36
1.16–4.63
0.82–4.04
0.20–3.19
0.87–1.77
0.82–1.68
0.89–4.45
0.43–3.01
0.78–1.60
0.70–1.55
0.61–2.68
0.50–8.11
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variance in autoimmune TDs is due to genetic effects.39 In 
our study, the identified higher risk in the offspring may be 
driven by the child inheriting a genetic mutation in this case 
stratified to their mother or by epigenetic modulations occur-
ring during in utero when exposed to autoantibodies. Hypo-/
hyperthyroidism or thyroid medications or even influence by 
pre-/postnatal environmental factors may also be contribut-
ing factors. Unfortunately, the current dataset derived from 
registers does not allow any conclusion regarding the effect 
of genetic, epigenetic, or other pre-/postnatal environmental 
exposures contributing to the increased risk of developing 
autoimmune disease in the offspring.
The validity of the captured information in studies 
based on the use of national registries is a core issue.40 We 
were able to identify maternal autoimmune TD by hospital 
diagnosis from the DNPR. The validity of the diagnosis of 
autoimmune TD registered in the DNPR is high, showing 
only misclassification in 2% of the cases according to a study 
based on biomarkers.2 Only women with active autoimmune 
TD, who had a hospital contact with the relevant diagnoses 
within 1 year before childbirth, were considered part of the 
exposed cohort in our study. For both Hashimoto’s thyroid-
itis and Graves’ disease, we found that a higher proportion 
of the women were diagnosed during the years 2004–2013, 
compared to the periods before 2004. This may be due to a 
larger proportion being diagnosed with increasing awareness 
of these diseases during pregnancy – noting that the inclu-
sion criterion was a diagnosis within 1 year of child birth. It 
could also be related to a genuine increase in the incidence 
of the two diseases during the last part of our study period 
or could be related to the registration of diseases in the reg-
istries. Unfortunately, the registers available do not comprise 
patients assigned with the diagnoses by the general practi-
tioner (GP). When pregnant, patients with especially newly 
diagnosed TD are expected to be referred from the GP to the 
hospital for treatment. Our study has several  methodological 
Figure 2 hr and adjusted hr (bold) for chronic disease in the offspring of mothers with hashimoto’s thyroiditis during pregnancy, log scale.
Notes: TD included all types of TDs and graves’ disease and hashimoto’s thyroiditis as subgroups. adjustments were only made in groups with more than ten outcomes or 
a significant result in the crude analysis. Crude HRs were adjusted for sex of the child, year of birth, maternal age at birth, delivery mode, multiple birth, birth order, preterm 
birth, sga, and maternal comorbidity of the outcome disease. TD included the following diagnoses: iCD-8: 240, 241, 242 (except 242.00), 243, 244 (except 244.01), 246, 
245.02, 245.03, 245.04, 245.08; iCD-10: E00, E01, E02, E03, E04, E05 (except E05.0), E06, E07. graves’ disease consisted of the following diagnoses: iCD-8: 242.00, 242.01, 
242.08, 242.09; and iCD-10: E05.0. hashimoto’s thyroiditis consisted of the following diagnoses: iCD-8: 244.01 and iCD-10: E06.3, 06.3a, E06.3B.
Abbreviations: Exp, exposed; HR, hazard ratio; ICD, International Classification of Diseases; SGA, small for gestational age; TD, thyroid disease; Unexp, unexposed.
Disease Exp760
Unexp
1,557,577 HR 95% Cl
Chronic lung disease, including asthma
TD
- Graves’ disease
- Hashimoto’s thyroiditis
Parathyroid diseases
Type 1 diabetes
Type 2 diabetes
Polycystic ovary syndrome
Epilepsy
Multiple sclerosis
Rheumatoid arthritis
Systemic lupus erythematosus
Inflammatory bowel disease
Coagulation disorders
Anxiety and personality disorders
Affective mood disorders
Schizophrenia and other paranoid 
psychoses
6
8
1
2
0
1
0
0
5
0
2
0
0
0
6
0
2
44,106
4,404
542
705
213
5,106
576
1,854
19,997
296
4,518
293
4,574
2,513
28,287
5,645
5,777
0.87
13.21
11.12
27.65
0.87
29.49
24.02
1.16
2.14
8.44
0.20 0.50 1.0 2.0 5.0
HR
Crude
Adjusted
10.0 20.0 50.0 100.0
0.94
2.24
0.39–1.93
6.60–26.46
5.53–22.31
3.88–197.06
0.87–0.87
7.34–118.51
5.89–97.97
0.16–8.25
0.97–4.72
2.18–32.63
10.64 2.80–40.41
0.39–2.27
0.56–8.97
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strengths including the size of the study population and 
the population-based approach using valid and complete 
registries. We have complete follow-up of all children in 
our cohorts, and the examined outcomes in the registers can 
be assessed independently of the exposure status, thereby 
reducing both selection and information bias. Even so, some 
information bias cannot be ruled out if physicians are more 
prone to diagnose diseases in the offspring of mothers with 
TD compared to children born to mothers without TD and 
detection bias would thus be induced. Furthermore, we were 
able to take important potential confounders into account (eg, 
calendar time of birth, preterm birth, and maternal comorbid-
ity) that were based on valid information from the DMBR 
and the DNRP. In the exposed cohort, we only included 
women who were diagnosed with TD within 1 year before 
childbirth in order to ensure that maternal autoimmune TD 
was actively present during pregnancy. In addition, it is an 
important strength of the study that we examined the risk of 
a large number of different chronic diseases in childhood 
and adolescence and had not selected only a single or a few 
disease categories in the offspring.
Our study has some limitations. Firstly, we cannot rule 
out that some of the diagnoses on the child outcomes are 
misclassified. Secondly, the results on schizophrenia and 
other paranoid psychoses that were based on only two child 
outcomes should be interpreted carefully. Thirdly, for some 
of the disease categories with only a few outcomes (eg, 
Graves’ disease and Hashimoto’s thyroiditis in children born 
to mothers with Hashimoto’s thyroiditis during pregnancy 
and Hashimoto’s disease in children born to mothers with 
Graves’ disease during pregnancy), we had low statistical 
precision. Furthermore, when examining the health effect in 
the offspring, it is valuable to have as many years of follow-up 
as possible; but the length of follow-up in this study is limited 
by the onset of the nationwide registries, although we used 
as long follow-up periods as possible based on data from the 
registries. For some of our outcomes (eg, psychiatric disorders, 
PCOS, and asthma), it would have been especially valuable to 
have longer follow-up time in the children, as these diseases 
are diagnosed in late childhood/adolescence. We did not have 
outcome data on children only diagnosed by the GP, but as we 
are examining serious chronic diseases in the children, virtu-
ally all children suspected for these diseases will be referred 
for exact diagnosis and treatment in a hospital setting.
Conclusion
Our data suggest that children born to women with active 
Graves’ disease and Hashimoto’s thyroiditis have excess 
long-term morbidities in childhood and adolescence. We 
particularly found an increased risk of TD and type 1 diabe-
tes in children exposed in utero to Graves’ disease. Whether 
these findings reflect the TD exposure in early life, exposure 
to thyroid antibodies, the medical treatment of the maternal 
disease, genetics, epigenetics, or environmental aspects still 
needs to be clarified in future studies.
In the pediatric setting, children with TDs are frequently 
diagnosed late in disease progression, when suffering from 
growth delay, and concentration, learning, and attention dif-
ficulties. Based on our results, we find it relevant to consider 
especially TD in children who are exposed to active maternal 
TD during pregnancy, and attention to type 1 diabetes should 
also be paid to children exposed in utero to Graves’ disease. 
Hopefully, an increased awareness of both GPs and pedia-
tricians on this association between the exposure to active 
maternal TD during fetal life and later development of disease 
in the offspring may result in early diagnosis and, thereby, pre-
vention of severe developmental delay in the diseased child.
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Supplementary material
Table S1 ICD-8 and ICD-10 classification diagnostic codes used
Diseases ICD-8 ICD-10
rheumatoid arthritis 712.09 (in children), 712.19, 712.29, 712.39, 
712.59
M05, M06 (excluding M06.1)+M08 (children)
Type 1 diabetes and type 2 diabetes 249.XX, 250.XX E10+E11
Thyroid diseases 240.XX, 241.XX, 242.XX, 243.XX, 244.XX, 
245.02, 245.03, 245.04, 245.08, 246.XX
E00-E07
graves’ disease
hashimoto’s thyroiditis
242.00, 242.01, 242.08, 242.09
244.01
E05.0
E06.3, E06.3a+E06.3B
Parathyroid diseases 252.XX E21+E20
Polycystic ovary syndrome 256.9 E28.2
systemic lupus erythematosus 734.19, 716.09, 734.09, 734.90 M32.1, 32.2, 32.3, M33, M34 (excluding M34.2), 
M35.0
Inflammatory bowel disease 563.XX, 569.04 K50+K51
Epilepsy 345.XX g40+g41
Multiple sclerosis 340.XX g35
Coagulation disorders 286.XX D66-68
Chronic lung disease, including asthma 491.XX, 492.XX, 493.XX (excluding 493.01) J42-45+J47+J60-67+J70 (excluding J70.0, 
J70.2)+J84.0 J84.8 J84.9
affective mood disorders 296.XX, 298.09, 298.19, 300.49, 301.19, 790.29 F31, F33, F34.1, F06.32, F38.08, F39.9
schizophrenia and other paranoid psychoses 295.XX, 297.XX, 298.39, 301.83 F20-F29 (excluding F23)
anxiety and personality disorders 300.XX (excluding 300.49), 301.XX (excluding 
301.19), 299.00, 299.01
F40, F60, F84.0, F84.1, F84.5, F84.8, F84.9
Abbreviation: ICD, International Classification of Diseases.
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